Alterations in thyroid hormone status and the administration of radiographic contrast agents can markedly influence iodothyronine metabolism and, in particular, the activity of type I 5'-deiodinase (5'DI). In the present studies, the mechanisms responsible for these effects have been reassessed. As previously reported, the addition of iopanoic acid (IOP) to broken cell preparations resulted in a competitive pattern of 5'DI inhibition. However, the in vivo administration to rats of IOP or 3,3',5'-triiodothyronine (rT3) resulted in a noncompetitive pattern of inhibition of 5'DI in the liver, kidney, and thyroid gland, whereby marked decreases in maximal enzyme velocity (V max) were noted, with no change in the value of the Michaelis-Menten constant. In rats rendered hyperthyroid by the injection of 3,5,3'-triiodothyronine (T3), 5'DI activity was significantly increased in the liver and the kidney. The administration of IOP to these thyrotoxic animals resulted in a rapid loss of enzyme activity characterized by an approximate 80% decrease in 5'DI V max values in both tissues. Furthermore, this inhibitory effect persisted for longer than 60 h after a single IOP injection. IOP administration also decreased 5'DI V max levels in the thyroid gland by 52%. In other experiments, treatment of intact Reuber FAO hepatoma cells with IOP or rT3 induced a rapid decrease in 5'DI V max levels. In cells treated with cycloheximide, these agents […] 
Introduction
Alterations in thyroid hormone status and the administration of radiographic contrast agents can markedly influence iodothyronine metabolism and, in particular, the activity of type I 5'-deiodinase (51I). In the present studies, the mechanisms responsible for these effects have been reassessed. As previously reported, the addition of iopanoic acid (1OP) to broken cell preparations resulted in a competitive pattern of 5DI inhibition. However, the in vivo administration to rats of IOP or 3,3',5'-triiodothyronine (rT3) resulted in a noncompetitive pattern of inhibition of 51)I in the liver, kidney, and thyroid gland, whereby marked decreases in maximal enzyme velocity (Vx) were noted, with no change in the value of the Michaelis-Menten constant. In rats rendered hyperthyroid by the injection of 3,5,3'-triiodothyronine (T3), 5DI activity was significantly increased in the liver and the kidney. The administration of IOP to these thyrotoxic animals resulted in a rapid loss of enzyme activity characterized by an approximate 80% decrease in 5DI V.,,, values in both tissues. Furthermore, this inhibitory effect persisted for longer than 60 h after a single IOP injection. IOP administration also decreased 51)I V.,. levels in the thyroid gland by 52%. In other experiments, treatment of intact Reuber FAO hepatoma cells with IOP or rT3 induced a rapid decrease in 5DI V.,., levels. In cells treated with cycloheximide, these agents enhanced the rate of disappearance of enzyme activity by > 12-fold, indicating a predominant effect on accelerating the rate of enzyme inactivation and/or degradation. These studies demonstrate that iodothyronines and other iodinated compounds have complex regulatory effects on 5DI that entail alterations in the rates of both enzyme activation and inactivation. The previously accepted concept that rT3 and IOP impair thyroxine (T4) to T3 conversion in vivo by acting as competitive inhibitors is an oversimplification. Rather, the clinically beneficial effects of administering these agents to patients with hyperthyroidism may result primarily from the rapid and prolonged inactivation of 51)I which occurs in the thyroid gland and peripheral tissues.
The hyperthyroid state associated with Graves' disease is characterized by a marked increase in the rate ofboth the thyroidal secretion and the peripheral production of 3,5,3'-triiodothyronine (T3)' (1) . The resultant elevations in the circulating and tissue T3 concentrations lead to functional changes in a number of organ systems and thus produce the characteristic signs and symptoms of this disorder.
Alterations in thyroid hormone status also have important and direct "autoregulatory" effects on the cellular processes that metabolize these hormones (2) . In the rat, hyperthyroidism results in a marked increase in the rate of "local" T3 production in the liver (3, 4). This effect is secondary, in part, to an increase in activity of type I 5'-deiodinase (51DI), the principal enzymatic process responsible for hepatic thyroxine (T4) to T3 conversion (5) . In contrast to this activating effect of thyroid hormones on 5'DI in the liver (and kidney [6] ), type II 5'-deiodinase (5'DII) activity in the anterior pituitary gland and central nervous system is suppressed in hyperthyroid animals, and T3 neogenesis in these tissues is markedly decreased (2, 3) . The autoregulatory effects of thyroid hormones on 51DI and 5'DII thus differ significantly. As a consequence, the 5'DI present in the liver and kidney is likely to be the principal process mediating the extrathyroidal conversion of T4 to T3 in the hyperthyroid state.
Radiographic contrast agents such as iopanoic acid (IOP) and sodium ipodate (NaIp) inhibit T4 to T3 conversion in man (7) (8) (9) and experimental animals (10) (11) (12) , and offer an alternative to the thionamides in the treatment ofGraves' disease ( 13, 14) . When administered to hyperthyroid patients, these agents induce a marked decrease in the serum T3 concentration which occurs more rapidly than that noted after the administration of stable iodine (15) or 6-n-propyl-2-thiouracil (PTU) (16) . The rapidity with which radiographic contrast agents lower T3 levels may be of considerable clinical importance. In a recent study of thyrotoxic patients with severe cardiac manifestations, the amelioration of clinical symptoms after NaIp administration paralleled the fall in serum T3 levels; significant improvements in several cardiovascular parameters were noted as early as 3 h after a single dose (17) .
In tissue homogenates, IOP and NaIp act as competitive inhibitors of both 5DI (18) (19) (20) and 51)II (21, 22) , and this has previously been assumed to be the mechanism whereby they inhibit T3 neogenesis in vivo. We have recently demonstrated, however, that these agents inhibit T4 to T3 conversion in the anterior pituitary gland and cerebral cortex in vivo by noncompetitively and irreversibly inactivating the 5D11 enzyme (23) . This process of inactivation involves a unique mechanism of enzyme regulation that may be initiated by the direct interaction of ligands (e.g., substrates such as T4 or 3,3',5'-triiodothyronine [reverse T3, rT3J, or competitive inhibitors such as 1OP) with the 5DII active site. Furthermore, this ligand-induced inactivation of 5DII is modulated by the cellular thiol/disulfide balance (23) .
These findings regarding the regulation of 5DII prompted us to investigate the mechanisms whereby thyroid hormones, radiographic contrast agents, and sulfhydryl oxidizing agents regulate 5DI in several tissues of the rat. Our results demonstrate that 5DI is regulated in a manner considerably more complex than previously believed, and that this enzymatic process in the liver, kidney, and thyroid gland is subject to ligand-induced inactivation in a fashion analogous to that previously delineated for 5DIL. (29) .
Methods
Ascending paper chromatography was performed using a tertial amyl alcohol/2 N ammonium hydroxide (1:1) solvent system as described by Galton and Hiebert (30) . TLC was performed as described by van Protein concentrations were determined by the method of Lowry et al. (32) . Aliquots of tissue samples containing DTT were precipitated with TCA before the determination of protein content (33) .
All results are given as the mean±SE. Statistical analysis was performed using the paired and unpaired t test with the Bonferroni correction applied when multiple comparisons were made (34). Alternatively, Dunnett's t test was used when multiple comparisons were made with a control group (35) .
Results
Regulation of S'DI in kidney and liver. As and 66%, respectively. The finding that Km values were unchanged in this (Table I) , as well as in subsequent experiments, indicates that the amount of IOP carried over into the in vitro 5DI assay system was insufficient to cause competitive inhibition of '25I-rT3 deiodination.
The effects of the chronic administration of T3, rT3, and 1OP on the regulation of 5DI in the kidney and liver were examined in a second group of thyroidectomized rats (Fig. 3 ).
Twice daily, injections of rT3 (50 jtg/lOO g BW) or IOP (100 ,ug/I00 g BW) resulted in a marked and significant decrease in Vm.. values in both tissues. In contrast, the administration of T3 in a dose designed to render the animals hyperthyroid (0.6 ,ug/100 g BW, twice daily) increased 5DI activity to levels 10-fold greater than those observed in hypothyroid animals and two-to threefold greater than those present in a control group of euthyroid rats of the same age. The ability of rT3 and 1OP to antagonize the stimulating effects ofT3 were also examined (Fig. 3) . 5)DI activity in hyperthyroid animals was unchanged after a single injection of rT3 (50 g/lI00 g BW) or TOP (100 ,ug/100 g BW). However, injection of a single larger dose of lOP (4 mg/100 g BW), comparable in amount to that used in treating hyperthyroid patients with Graves' disease, resulted in a 78 and 85% decrease in V.. values in the liver and kidney, respectively. This inhibition by IOP in thyrotoxic animals resulted in levels of 5DI activity that were less than or similar to Fig. 4 . On such plots, the Vma. value is represented by the yintercept, whereas the Km value is equal to the negative value of the slope (26) . The time course of the in vivo inhibitory effects of IOP on 5DI in hyperthyroid animals was investigated in another experiment in which rats were treated chronically with T3 (1 Asg/I00 g BW, s.c., twice daily) and then were administered a single intravenous dose of IOP (4 mg/100 g BW) at 5, 12, 24, or 60 h before killing (Fig. 5 ). In the 24-and 60-h treatment groups, T3 administration was continued until 12 h before killing. Hyperthyroid animals again demonstrated significantly higher 5DI activity in the liver and kidney when compared with euthyroid control rats. IOP administration resulted in an inhibition of Vm., values in both tissues which was rapid in onset and prolonged in duration. The maximal inhibitory effects of 77 and 84% in liver and kidney, respectively, were similar to those noted previously and occurred at 5-12 h after Effects of IOP on S'DI activity in the thyroid gland. 51DI activity has been reported to be increased in the thyroid gland of patients with Graves' disease (36, 37) . Similar increases in activity have been noted in the thyroid glands of rodents that were administered thyroid-stimulating hormone (TSH) (38) or Igs from patients with Graves' disease (39), or rendered hypothyroid by the chronic administration of MMI (40) . To determine whether radiographic contrast agents inhibit 5DI Vm.. levels in thyroid tissue, rats made goitrous by the inclusion of MMI in their drinking water were injected intravenously with a single dose of IOP (4 mg/100 g BW) and then killed 5 or 12 h later. In contrast to a previous report (40) , 5DI activity in the thyroid glands of MMI-treated rats was not different from that determined in euthyroid control rats ofthe same age (Table II) . IOP administration, however, resulted in a significant decrease in Vmax levels at both time points. At tion, 5DI activity was decreased by 29% (P < 0.05), whereas at the 12-h time point activity was reduced by 52% (P < 0.005).
IOP administration did not alter Km values in either treatment group. Thus, as is the case in the liver and the kidney, radiographic contrast agents inhibit 51DI in the thyroid gland in vivo by a noncompetitive mechanism.
Regulation ofS'DI in the Reuber FAO hepatoma cell line. The suitability of Reuber FAO hepatoma cells to serve as a model system for studying the regulation of 5DI activity was investigated. Phenolic ring deiodinase activity was easily demonstrated in FAO cell sonicates using 251I-rT3 as substrate.
Characterization of this deiodinating process revealed the following: (a) 125I-release from '25I-rT3 was thiol-dependent with maximal product formation noted at DTT concentrations of 5-20 mM; (b) no 1251-production was noted in cell sonicates incubated at 0-40C or in sonicates previously heated to 80'C for 30 min; (c) 1251-production varied linearly with sonicate protein content up to 2.5 mg/ml; (d) as determined by paper chromatography, equal quantities of I-and 3,3'-diiodothyronine were formed from 251I-rT3; (e) in the presence of 20 mM dithiothreitol, PTU at a concentration of 1 mM inhibited 1251-production by > 99%; (f) using 1 nM '25I-T3 as a substrate, no phenolic or tyrosyl ring deiodinating activity could be demonstrated in cell sonicates under routine assay conditions; (g) '251-formation decreased somewhat with time of assay incubation; calculated deiodinase activity at the end of a 40-min incubation period was decreased by -30% from that determined during a 10-min incubation. The dependency ofthe inhibitory effects of IOP and rT3 on protein synthesis was investigated using FAO cells incubated with cycloheximide (Fig. 7) . The addition of 50 Mg/ml cycloheximide to the culture medium inhibited [3H]leucine incorporation into TCA-precipitated material by > 95%. In spite of this inhibition of protein synthesis, cycloheximide treatment for 6 h decreased 5DI activity in FAO cells by only 5±2% (n = 4 experiments) compared with untreated control cells. Cycloheximide did not block the inhibitory effects ofrT3 and IOP on 5DI activity. The addition of rT3 (1 AM) or IOP (10 MAM) to cycloheximide-treated cells resulted in a 42±9 and 53±10% decrease (P < 0.01 for either group vs. cycloheximide treatment alone) in enzyme activity, respectively, after a 6-h incubation. Thus, inhibition of 5DI by these agents is due to an enhanced rate of enzyme inactivation and/or degradation.
A striking feature of the regulation of phenolic ring deiodination in GH3 pituitary tumor cells is that exposure of intact cells to the sulfhydryl oxidizing agent diamide results in a rapid inactivation of 5DII activity which mimicks the effects of rT3, IOP, and other ligands (23) . Analogous findings were demonstrated in FAO hepatoma cells treated with diamide (Fig. 8) .
In three experiments where intact cells were incubated for 3.5 h with 0.4 mM diamide, 5DI Vmax levels decreased by 75±4% (P < 0.025), whereas Km values were unaltered. Given the prior observation that the inhibition of protein synthesis for 6 h in FAO cells resulted in only a minimal loss of 5DI activity, the rapidity of the diamide effect necessitates that the mechanism involved is an enhanced rate of enzyme inactivation. In these experiments, cells were maintained during the 3.5-h incubation period in glucose-free medium to inhibit the reformation ofglutathione (41) . 5DI activity in control cells maintained in this medium did not differ from that noted in cells maintained concurrently in the same medium supplemented with glucose 6- o. C> " 4-EP R 8 .h Lzl.. (2 mg/ml). The inhibitory effect of diamide in these experiments was not due to interference in the in vitro 5DI assay system; the addition of 1 mM diamide to FAO cell sonicates did not alter 51)I activity when 20 mM DTT was present in the reaction mixture.
Discussion
The two enzymatic pathways that convert T4 to T3 (i.e., 5DI and 51DII) have been previously distinguished by differences in kinetic characteristics, susceptibility to inhibition by PTU, tissue distribution, and response to alterations in thyroid hormone status (42) . Whereas hyperthyroidism in the rat leads to increased 5DI activity (5, 6) , the activity of 5DII is markedly suppressed due to an unusual, and as yet incompletely understood process, which we have termed ligand-induced inactivation (23) . The seminal finding of the present studies is that substrates and competitive inhibitors also induce the inactivation of 5DI in vivo. This finding has significant implications for our understanding of the cellular mechanisms that regulate thyroid hormone economy. Inactivation of phenolic ring deiodinases. In the experiments reported herein, the administration of iodinated compounds that are devoid of thyromimetic activity (i.e., rT3 or IOP) to experimental animals or cultured cells resulted in a rapid and prolonged suppression of 5DI activity that was characterized by a decrease in Vm. with no change in Km. These effects on 5DI in hepatic and renal tissue are exactly analogous to those previously defined for 51II in the anterior pituitary gland and cerebral cortex (23) . Furthermore, the inhibitory effects of ligands on these processes are independent of protein synthesis and are, therefore, secondary to an enhanced rate of enzyme inactivation and/or degradation. In the case of the 5DI present in FAO cells, rT3 and IOP enhanced the rate of loss of enzyme activity by greater than 12-fold, assuming that the disappearance of activity after cycloheximide treatment is exponential.
Sato et al. (41) have previously reported that diamide treatment impairs the conversion of T4 to T3 by intact, cultured rat hepatocytes. Their studies, however, did not determine whether the decrease in T3 formation was due to a decrease in the availability of a necessary thiol cofactor or if it was secondary to an effect on 5DI synthesis or inactivation. The present experiments demonstrate that this inhibitory effect of diamide on iodothyronine metabolism is due to a rapid inactivation of 5DI. We have previously demonstrated that ligand-induced inactivation of 5DII is also influenced by the cellular thiol/disulfide balance; the exposure of intact GH3 cells to sulfhydryl oxidizing agents rapidly inactivates the enzyme, whereas exposure to sulfhydryl reducing agents protects against the substrate-induced loss of activity (23) . Thus, the present finding that diamide rapidly inactivates 5DI in intact FAQ cells provides another important parallel in the regulation of the two phenolic ring deiodinase processes.
Of note, however, is that the 5DI process appears to be considerably less sensitive than the 5DII one to ligand-induced inactivation. Under experimental conditions where enzyme activity is increased (hypothyroidism for 5DII; hyperthyroidism for 5DI), a single injection of 0.04 mg IOP/00 g BW inactivates > 80% of 5DII in the anterior pituitary gland and cerebral cortex (23) , yet has no effect on 51)I in the liver or kidney (Fig. 3) . Indeed, a 70-80% inhibition of 5DI activity is only achieved when hypothyroid or hyperthyroid rats are administered a 100-fold larger dose of IOP (Table I and Fig. 3) . Similarly, a single dose of rT3 of 50 ztg/100 g BW, which has been demonstrated by other investigators to inhibit 5DII activity in the pituitary gland and cerebral cortex by > 90% (43), had no effect on 5DI activity when administered to hyperthyroid animals in the present studies. Results from our cell culture studies provide additional evidence that 5DI is less sensitive to ligand-induced inactivation. We have previously demonstrated that the concentration of IOP required to inhibit 5DII activity by 50% in intact GH3 cells that are maintained in serum-free medium is 0.005 IAM (23) . In the present experiments using FAO cells grown under analogous conditions, 50% inhibition of 5DI required a medium IOP concentration of 0.5 gm.
Taken together, these data suggest that 100-fold greater concentrations of ligand are required to inactivate 5'DI as compared with 5DIL. The reason for this marked difference in susceptibility to inactivation is uncertain, but could reflect tissue differences in either ligand concentration or the thiol/disulfide balance. Another intriguing possibility is suggested by our previous observation that the potency of a ligand in inactivating 5DII in intact GH3 cells is closely correlated with the ligand's Ki value as determined in broken cell preparations and indicative of the affinity of the ligand for the enzyme's active site (23) . The Ki values ofIOP for 51)I and 5DII are 8 AM (Fig.  1) and 0.05 ,M (23) , respectively, and therefore the affinity of 51)I for this ligand is about two orders of magnitude less than the affinity of 5DIL. Thus, if the cellular mechanisms that inactivate 5DI and 5DII are similar, the lesser potency of IOP that inactivates the former enzyme may reflect the fact that higher concentrations are required to interact with the 51DI active site and to initiate the inactivation process.
In addition to this difference in sensitivity, ligand-induced inactivation of 5DI is somewhat slower than that noted for 5DI. In intact GH3 cells, maximal inactivation of 5DII by ligands is noted after a 1-2-h incubation period (23) , whereas in the FAO cells used in the present experiments, a 3-h incubation period with rT3 or IOP resulted in only half-maximal inhibitory effects. Of further note is that compared with the 50-min half-life of 5DII activity in GH3 cells and other rat tissues (44) , the turnover of 5DI in FAO cells appears to be considerably slower, with only a 5% loss of enzyme activity after a 6-h treatment of cells with cycloheximide.
Dual mechanism of control of 5'DI by iodinated compounds. The present results demonstrate that iodothyronines and other iodinated compounds have complex regulatory effects on 5DI in the liver and kidney. As demonstrated herein, and previously reported by other investigators (4-6), 5DI is activated by the chronic administration of the metabolically active thyroid hormones T3 or T4. Ligands for the enzyme which have little or no thyromimetic activity (i.e., rT3 and IOP), however, inactivate this enzymatic process and can, when present in high concentrations, counteract the stimulatory effects of T3 on 5DI. Whether this activation and inactivation represent changes in enzyme synthesis and degradation remains uncertain.
Over the last three decades, investigators have observed that the administration of rT3 to patients or laboratory animals, in amounts considerably larger than those used in the present study, counteracts the thyrotoxic state and antagonizes the effects of T4 (45) (46) (47) (48) . Such treatment has also been demonstrated to decrease hepatic T4 to T3 conversion (49) , an effect which has previously been attributed to the competitive effect of rT3 on T4 deiodination that was noted in vitro (10, 50) . Recently, Han et al. (51) reported that rT3 also antagonizes the induction of 5DI by insulin, cortisol, and T3 in cultured fetal mouse liver cells. It was uncertain from their study, however, which processes mediated this rT3 effect. The present findings provide a better understanding of the cellular mechanisms that underlie these observations. Our findings do not negate the possibility that rT3, when present in high concentrations, competes in vivo with T4 as a substrate for phenolic ring deiodination. Rather, our results suggest that in so doing, the large ligand load presented by rT3 rapidly inactivates 51DI, and that this is likely to contribute significantly to the impairment observed in T3 production.
Radiographic contrast agents for the treatment for hyperthyroidism. Radiographic contrast agents have been used successfully to treat the hyperthyroid state that accompanies Graves' disease in adults (13, 14, 17) . Recent reports have also demonstrated the therapeutic value of administering these agents to patients with neonatal Graves' disease (52) and thyrotoxicosis factitia (53) . IOP and NaIp offer several practical advantages when used as treatments for these conditions. They can be administered infrequently (13, 14) , are generally well tolerated during chronic therapy (14) , and rarely cause hypersensitivity reactions (52) . In addition, the rapidity with which serum T3 levels are lowered may have important clinical benefits (17) .
The present findings provide new insights into the mechanisms whereby radiographic contrast agents alter thyroid hormone economy in thyrotoxicosis. The inactivating effect of IOP on 5DI in hyperthyroid rats was noted to be rapid in onset and long-lasting in duration. Maximal inactivation was noted within 5 h, and significant effects persisted for 60 h after a single dose despite continued T3 administration. In the clinical setting, the inhibitory effect would be likely to persist even longer, as the rapid lowering of serum and tissue T3 levels would decrease the stimulus for 5DI activation. These results correlate well with clinical observations that serum T3 levels in hyperthyroid patients decrease 60% during the first 24 h of treatment with these agents (15, 16) and that they need be administered only once every 3 d (13) .
In a recent study, Wang et al. (54) reported that a fixed dose of IOP (500 mg/d and equivalent to -1 mg/100 g BW in the patients studied) resulted in the long term normalization of serum T3 concentrations in only 45% of patients with Graves' disease. Given the present finding that the inactivating effects of radiographic contrast agents on 5DI are dose-dependent, the therapeutic use of these agents in treating hyperthyroidism may require that the dosage be titrated to achieve optimal effects. The thyroid gland in patients with Graves' disease demonstrates increased 51DI activity (36, 37) and enhanced secretion of T3 (55) . Indeed, Laurberg (56) has recently demonstrated that both endogenous T4 (that is, T4 derived from thyroglobulin) and circulating T4 are deiodinated to T3 in this organ. The present finding that 5DI in the thyroid gland is also subject to rapid inactivation by IOP provides an explanation for the previous observations that radiographic contrast agents inhibit thyroidal T3 secretion in vivo (57) and 51DI activity in vitro (38, 58 ).
In conclusion, we have demonstrated that 5DI is subject to ligand-induced inactivation, an observation which corrects prior misconceptions concerning the mechanism whereby iodothyronines and other iodinated compounds inhibit T4 to T3 conversion in vivo. Although this inactivation process appears to be analogous to that previously delineated for 5DII, the role ofthis mechanism in regulating the activity of these two enzymatic pathways appears to differ. Whereas inactivation by substrate is the principal mechanism controlling 5DII activity (44) , it seems unlikely that this process influences 5DI activity under physiologic or even pathologic conditions; the predominant effect of T4 on 5DI is one of activation (5, 6, 59 ) and rT3 concentrations are probably insufficient to exert a significant inactivating effect (49) . However, the inactivation of 5DI is of major pharmacologic importance when the radiographic contrast agents are used to treat hyperthyroid patients. At present, the biochemical processes that mediate the inactivation of the phenolic ring deiodinases remain uncertain. A greater understanding of this unusual mechanism of enzyme regulation is likely to have important theoretical and clinical consequences.
